Skip to main content

Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant



The COVID-19 pandemic is caused by the betacoronavirus SARS-CoV-2. In November 2021, the Omicron variant was discovered and immediately classified as a variant of concern (VOC), since it shows substantially more mutations in the spike protein than any previous variant, especially in the receptor-binding domain (RBD). We analyzed the binding of the Omicron RBD to the human angiotensin-converting enzyme-2 receptor (ACE2) and the ability of human sera from COVID-19 patients or vaccinees in comparison to Wuhan, Beta, or Delta RBD variants.


All RBDs were produced in insect cells. RBD binding to ACE2 was analyzed by ELISA and microscale thermophoresis (MST). Similarly, sera from 27 COVID-19 patients, 81 vaccinated individuals, and 34 booster recipients were titrated by ELISA on RBDs from the original Wuhan strain, Beta, Delta, and Omicron VOCs. In addition, the neutralization efficacy of authentic SARS-CoV-2 wild type (D614G), Delta, and Omicron by sera from 2× or 3× BNT162b2-vaccinated persons was analyzed.


Surprisingly, the Omicron RBD showed a somewhat weaker binding to ACE2 compared to Beta and Delta, arguing that improved ACE2 binding is not a likely driver of Omicron evolution. Serum antibody titers were significantly lower against Omicron RBD compared to the original Wuhan strain. A 2.6× reduction in Omicron RBD binding was observed for serum of 2× BNT162b2-vaccinated persons. Neutralization of Omicron SARS-CoV-2 was completely diminished in our setup.


These results indicate an immune escape focused on neutralizing antibodies. Nevertheless, a boost vaccination increased the level of anti-RBD antibodies against Omicron, and neutralization of authentic Omicron SARS-CoV-2 was at least partially restored. This study adds evidence that current vaccination protocols may be less efficient against the Omicron variant.

Peer Review reports


SARS-CoV-2 is the etiological agent of the severe pneumonia COVID-19 (coronavirus disease 2019) [1, 2]. A new variant B.1.1.529 of the betacoranavirus SARS-CoV-2 was identified in late November 2021 and has rapidly been classified as a variant of concern (VOC) by the WHO and named Omicron [3]. The Omicron variant shows a high number of mutations in the SARS-CoV-2 spike protein in comparison to the previously described VOCs Alpha [4], Beta (B.1.351) [5], Gamma (P.1) [6], and the currently dominating Delta variant (B.1.617.2) [7]. The first sequenced Omicron variant (GISAID accession ID EPI_ISL_6913995, collection date 2021-11-08, South Africa) contains a total of 36 mutations compared to the original Wuhan strain and includes 29 amino acid (aa) changes, six aa deletions, and one aa insertion. Fifteen of these mutations are concentrated in the N-terminal receptor-binding domain (RBD) of the spike protein which binds to the human zinc peptidase angiotensin-converting enzyme 2 (ACE2) for cell entry [8, 9].

Importantly, the RBD is targeted by more than 90% of the neutralizing serum antibodies, making it the most relevant target for SARS-CoV-2 neutralization [10, 11]. Consequently, the majority of therapeutic antibodies for the treatment of COVID-19 are designed to interact with this part of the SARS-CoV-2 spike protein [12, 13]. The abundant mutations in spike might indicate that the Omicron variant may bind with a different affinity to the ACE2 receptor, therefore may be altering its cell entry characteristics. Simultaneously, the mutations may help the virus to escape the immune recognition by antibodies, facilitating viral spread in a seropositive population.

While initial studies have shown a severe reduction in serum neutralizing capacity of vaccinated and convalescent patients against the Omicron variant [14,15,16], it is unclear to which extent the RBD domain mutations contribute to this loss in neutralization activity. Additionally, while several mutations present in Omicron are computationally predicted to increase ACE2 binding affinity, others are predicted to reduce its affinity [17].

The aim of this study is the analysis of the new Omicron RBD and unravel why the Omicron variant is displacing other variants. Therefore, the binding of ACE2 to the new Omicron RBD was determined in comparison to the original Wuhan strain and the Beta and Delta variants by two different techniques. Moreover, we tested the binding of human sera from COVID-19 hospitalized patients or vaccinated persons with 2× BNT162b2, 1× Ad26.COV2.S, or 2× mRNA1273 vaccines, as well as boost vaccinated persons, to the RBD of the original Wuhan strain, the Beta, the Delta, and the Omicron VOC. Furthermore, the neutralization efficacy of sera of 2× BNT161b2 and boost vaccinees was analyzed using the authentic SARS-CoV-2 virus.


Serum samples

Blood samples were obtained from non-vaccinated, intensive care unit (ICU) patients with severe symptoms from the second (pre-Alpha) and third (Alpha variant) pandemic wave in Croatia (Rijeka, sampling December 2020 to April 2021) and Italy (Pavia, sampling March 2020 to February 2021) or from vaccinated people in Germany (Braunschweig, sampling June 2021 to December 2021), Sweden (Stockholm, May 2021 to November 2021), and Italy (Pavia, February 2021 to January 2022) as indicated. While all voluntary donors were informed about the project and gave their consent for the study, consent requirement was waived by the ethical committee in Rijeka for patients in intensive care where sampling was a part of routine diagnostics. Ten out of the 17 patients of the Croatian cohort died by COVID-19 infection. The sampling was performed in accordance with the Declaration of Helsinki. The donors included adults of both sexes. The first WHO International Standard for anti-SARS-CoV-2 immunoglobulin (NIBSC code: 20/136) was used as positive control serum, and pre-pandemic negative control sera were provided by the LADR Braunschweig and did not bind to any RBD variant (data not shown). Approval was given from the ethical committee of the Technische Universität Braunschweig (Ethik-Kommission der Fakultät 2 der TU Braunschweig, approval number FV-2020-02). The study in Croatia was approved by the Ethics committee of the Rijeka Clinical Hospital Center (2170-29-02/1-20-2). The study in Italy was performed under the approval of the Institutional Review Board of Policlinico San Matteo (protocol number P_20200029440). The study in Sweden was approved by the ethics committee in Stockholm (Dnr 2020-02646).

Details about study participants are shown in Table 1.

Table 1 Used human serum samples in this study

Construction of the expression vectors

All sequences of the RBD variants (319-541 aa of GenBank: MN908947) were inserted in a NcoI/NotI compatible variant of the OpiE2 expression vector [18] containing an N-terminal signal peptide of the mouse Ig heavy chain and a C-terminal 6xHis-tag. Single-point mutations to generate the Beta and Delta variants of RBD were inserted into the original Wuhan strain through site-directed mutagenesis using overlapping primers according to Zheng et al. [19] with slight modifications: S7 fusion polymerase (Mobidiag) with the provided GC buffer and 3% dimethyl sulfoxide was used for the amplification reaction. The RBD Omicron variant was ordered as GeneString from GeneArt (Thermo Fisher) according to EPI_ISL_6590608 (partial RBD Sanger sequencing from Hong Kong), EPI_ISL_6640916, EPI_ISL_6640919, and EPI_ISL_6640917 including Q493K which was corrected later to Q493R. Table 2 gives an overview about the used variants.

Table 2 RBD variants used in this study (319-541 of GenBank: MN908947)

Expression and purification of the RBD variants

The different RBD variants were produced in the baculovirus-free High Five cell system [20] and purified as described before [21]. Briefly, High Five cells (Thermo Fisher Scientific) were cultivated at 27°C, 110–115 rpm in EX-CELL 405 media (Sigma Aldrich) at a cell density between 0.3 and 5.5 × 106 cells/mL. On the day of transfection, cells were centrifuged and resuspended in fresh media to a density of 4 × 106 cells/mL before 4 μg expression plasmid/mL and 16 μg/mL of linear PEI 40 kDa (Polysciences) was pipetted directly into the cell suspension. After 4–24 h, cells were supplemented with fresh media to dilute the cells ~1 × 106 cells/mL, and 48 h after transfection, culture volume was doubled. Cell supernatant was harvested 4 to 5 days after transfection by a two-step centrifugation (4 min at 180 ×g and 20 min at >3500 ×g) and then 0.2 μm filtered for purification. Immobilized metal ion affinity chromatography (IMAC) His tag purification of insect cell supernatant was performed with a HisTrap excel column (Cytiva) on Äkta system (Cytiva) according to the manufacturer’s manual. In a second step, the RBD domains were further purified by size exclusion chromatography (SEC) by 16/600 Superdex 200 kDa pg column (Cytiva).

Expression and purification of ACE2-hFc

The extracellular domain of ACE2 receptor (GenBank NM_021804.3) was produced in pCSE2.6-hFc expression vector in Expi293F cells (Thermo Fisher Scientific) as described before [22]. In brief, Expi293F cells were cultivated at 37°C, 110 rpm, and 5% CO2 in Gibco FreeStyle F17 expression media (Thermo Fisher Scientific) supplemented with 8 mM Glutamine and 0.1% Pluronic F68 (PAN Biotech). For transfection, 1 μg DNA and 5 μg of 40 kDa PEI (Polysciences) per mL transfection volume were diluted separately in 5 transfection volumes and then mixed for the formation of complexes (20–30 min). Afterwards, PEI:DNA complexes were added to 1.5–2 × 106 cells/mL. Forty-eight hours later, the culture volume was doubled by feeding HyClone SFM4Transfx-293 media (GE Healthcare) supplemented with 8 mM Glutamine and HyClone Boost 6 supplement (GE Healthcare) with 10% of the end volume. One week after transfection, the supernatant was harvested by 15 min centrifugation at 1500 ×g. Purification was performed on a 1-mL HiTrap Fibro PrismA (Cytiva) column on Äkta go (Cytiva) according to the manufacturer’s manual.

ACE2 binding to RBD analyzed by titration ELISA

ACE2 binding to the produced RBD variant antigens was analyzed in ELISA in triplicates where 300 ng RBD per well was immobilized on a Costar High binding 96-well plate (Corning, Costar) at RT for 1 h. Next, the wells were blocked by 330 μL 2% MPBST (2% (w/v) milk powder in PBS; 0.05% Tween20) for 1 h at RT and then washed 3 times with H2O and 0.05% Tween20 (BioTek Instruments, EL405). ACE2-hFc was titrated from 0.01 mg/mL down to 1 ng/mL and incubated 1 h at RT prior to another 3× times washing step. Detection was performed by goat-anti-hIgG(Fc) conjugated with HRP (1:70,000, A0170, Sigma) and visualized with tetramethylbenzidine (TMB) substrate (20 parts TMB solution A (30 mM potassium citrate; 1% (w/v) citric acid (pH 4.1)) and 1 part TMB solution B (10 mM TMB; 10% (v/v) acetone; 90% (v/v) ethanol; 80 mM H2O2 (30%)) were mixed). After addition of 1 N H2SO4 to stop the reaction, absorbance at 450 nm with a 620-nm reference wavelength was measured in an ELISA plate reader (BioTek Instruments, Epoch). EC50 were calculated with OriginPro Version 9.1, fitting to a five-parameter logistic curve.

Affinity measurement by microscale thermophoresis

The affinity measurements were performed as described before [23]. In brief, ACE2-hFc was labeled by the Protein Labeling Kit RED-NHS 2nd Generation (NanoTemper) according to the manufacturer’s protocol. A degree of labeling (DOL) of < 3 was achieved and 10 nM of the labeled ACE2-hFc was applied in the measurements. Titration of the RBD variants was done by a Precision XS microplate sample processor (BioTek) in 384-well plates. Measurement was performed in Monolith (Nanotemper) using Monolith NT. Automated Capillary Chips (NanoTemper). The Excitation-Power was set to 40% and MST-Power to medium. The timeframe of 0.5 s up to 1.5 s was chosen to analyze the data by the MO Affinity Analysis software (NanoTemper) by Hill fit. For all RBD variants, a signal response above 18 and a signal to noise above 40 was obtained.

Serum titration ELISA

For titration ELISA, sera were diluted 1:100 to 1: 9.19 × 107 in 384-well microtiter plates (Greiner Bio-One) coated with 30 ng/well of the respective RBD variant. In addition, all sera were also tested at the lowest dilution (1:100) for determination of unspecific cross-reactivity on Expi293F cell lysate (30 ng/well), BSA (30 ng/well), and lysozyme (30 ng/well). IgGs in the sera were detected using goat-anti-hIgG(Fc)-HRP (1:70,000, A0170, Sigma). Three-hundred-eighty-four-well liquid handling was performed with a Precision XS microplate sample processor (BioTek), EL406 washer dispenser (BioTek), and BioStack Microplate stacker (BioTek). OD450 nm-620 nm was measured in an ELISA plate reader (BioTek Instruments, Epoch) and its software Gen5 version 3.03 was used to calculate EC50 values, further expressed as relative potency towards an internal calibrant for which the Binding Antibody Unit (BAU) was calculated using the WHO International Standard 20/136 in relation to the original Wuhan strain RBD. The graphics were created by GraphPad Prism 9.1. Significance was calculated by pairwise non-parametric multiple comparison ANOVA (Friedman’s test) with Dunn’s multiple comparisons test, using the Wuhan wt RBD values as the reference value for all three VOCs, but Omicron data were shown separately for better illustration.

SARS-CoV-2 neutralization assays

SARS-CoV-2 strain G614 and VOCs (Delta and Omicron) were isolated from patients in Pavia and used for microneutralization assay [24, 25]. Briefly, 50 μL of the sample, starting from 1:10 in a serial twofold dilution series (up to 1:640), was added to two wells of a flat-bottom tissue-culture microtiter plate (COSTAR, Corning Incorporated), mixed with an equal volume of 100 Tissue Culture Infection Dose 50 (TCID50) of a SARS-CoV-2 strain, previously titrated and incubated at 33°C in 5% CO2. All dilutions were made in Eagle’s minimum essential medium with addition of 1% penicillin, streptomycin, and glutamine and 5 μg/mL of trypsin. After 1 h of incubation at 33 °C in 5% CO2, VERO E6 cells (VERO C1008 (Vero 76, cloneE6, Vero E6); ATCC® CRL-1586™) were added to each well. After 48 h of incubation at 33°C in 5% CO2, wells were stained with Gram’s crystal violet solution (Merck) plus 5% formaldehyde 40% m/v (Carlo ErbaSpA) for 30 min. Microtiter plates were then washed in running water. Wells were scored to evaluate the degree of cytopathic effect (CPE) compared with the virus control. Blue staining of wells indicated the presence of neutralizing antibodies. The neutralizing titer was defined as the maximum dilution giving a reduction of 90% of the CPE. The cut-off for positivity was ≥1:10. Positive and negative controls were included in all test runs.


The Omicron RBD shows a slightly reduced binding to ACE2

The RBD of the original Wuhan strain, the Beta, Delta, and the Omicron variants were produced in insect cells and purified by IMAC and SEC. The quality of the recombinant proteins was analyzed by SDS-PAGE (Additional file 1: Fig. S1). All RBDs were immobilized on plates and binding of the soluble receptor ACE2 was analyzed by ELISA (Fig. 1). The Omicron RBD showed a slightly reduced binding to ACE2 (EC50 150 ng/mL, respectively 5.6 nM) compared to the Wuhan strain RBD (EC50 120 ng/mL, 4.6 nM). In contrast, an increased binding to Beta (EC50 89 ng/mL, 3.4 nM) and Delta RBD (EC50 89 ng/mL, 3.4 nM) was measured in comparison to the Wuhan strain. The affinities were also determined by microscale thermophoresis (MST) (Table 3, Additional file 1: Fig. S2). Again, the measured affinity for the Omicron RBD was slightly lower compared to Beta and Delta.

Fig. 1
figure 1

RBD variants binding to human ACE2. 300 ng/well immobilized Wuhan wt, Beta, Delta, or Omicron RBD were detected with human ACE2 (fusion protein with human Fc part) in titration ELISA. BSA was used as a negative control. Experiments were performed in triplicates and mean values are given. EC50 were calculated with OriginPro Version 9.1, fitting to a five-parameter logistic curve

Table 3 RBD-ACE2 affinity measured by MST. All experiments were performed in titration in triplicates and analyzed by the MO Affinity Analysis software (NanoTemper) by Hill fit

Human sera of COVID-19 patients and vaccinated persons show a reduced binding to Omicron RBD

The binding of human sera from hospitalized COVID-19 patients (Fig. 2A), from people vaccinated 2× with BNT162b2 (Corminaty) (7–43 days after second immunization) (Fig. 2B), once with Ad26.COV2.S (Janssen COVID-19 Vaccine) (14–33 days after immunization) (Fig. 2C), 2× with mRNA1273 (Spikevax) (5–55 days after second immunization) (Fig. 2D), or from mRNA vaccine boost-recipient vaccinees (5–49 days after boost vaccination, first immunization 2×BNT162b2 or 1×Ad26.COV2.S) (Fig. 2E) was analyzed by ELISA on Wuhan, Delta, Beta, and Omicron RBD. A direct comparison of the binding to Omicron RBD of all five serum groups is given in Fig. 2F.

Fig. 2
figure 2

Human serum binding to SARS-CoV-2 Wuhan original strain, Beta, Delta, and Omicron RBD. A ELISA using sera from hospitalized COVID-19 patients. B ELISA using sera from 2×BNT162b2-vaccinated persons (7–52 days after 2nd immunization). C ELISA using sera from 1×Ad26.COV2.S-vaccinated (14–33 days 1st immunization). D ELISA using sera from 2×mRNA-1273 (5–55 days after 2nd immunization). E ELISA using sera from 2×BNT162b2 or 1× Ad26.COV2.S vaccinated + boosted with BNT162b2 or mRNA-1273 (5–49 days after 3rd or in case of Ad26.COV2.S 2nd immunization) binding to the Omicron variant. F Rearranged representation of the data presented in AE. The ELISAs were performed as single-point titrations. The software Gen5 version 3.03 was used to calculate EC50 values, further expressed as relative potency in respect to an internal calibrant, for which the Binding Antibody Unit (BAU) was calculated using the WHO International Standard 20/136 titrated on Wuhan wt as reference. The geometrical mean values and the 95% CI are given in the graphs. The graphics and statistical analysis were performed with Graphpad Prism 9.1. For AE: Friedman test with Dunn’s multiple comparisons test was performed on the four conditions per graph (WT, Beta, Delta, Omicron). For F: Kruskal-Wallis test with Dunn’s multiple comparisons test was performed. Geometric mean and 95% confidence interval are represented by error bars. Multiplicity adjusted P values are shown as follows: ns: P > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001

The sera of COVID-19 patients (Fig. 2A), 2× BNT162b2 (Fig. 2B), and 2× mRNA-1273 vaccinees (Fig. 2D) showed a highly significant reduction in binding to Omicron RBD compared to Wuhan RBD in a non-parametric pairwise analysis. This reduction was more pronounced than the one observed against Beta or Delta RBD binding assays. Ad26.COV2.S group (Fig. 2C) showed in general a very low binding to all RBDs tested, suggesting a clearly weak immunogenicity of this vaccine formulation or posology.

Boost recipients had still a lower serum antibody binding to Omicron RBD compared to Wuhan, Beta, and Delta (Fig. 2E). However, the boost increased significantly the amount of anti-Omicron RBD antibodies in comparison to both the sera of vaccinees and COVID-19 patients (Fig. 2F). Interestingly, no significant difference was observed for people vaccinated first with Ad26.COV2.S and subsequently boostered with BTN162b2 in comparison to persons 3× vaccinated with a mRNA vaccine (Additional file 1: Fig. S3).

Sera from vaccinated subjects show drastically reduced neutralization of authentic Omicron SARS-CoV-2 virus

The neutralization of authentic SARS-CoV-2 wt (with D614G mutation), Delta, and Omicron was analyzed using sera of 2× BNT162b-vaccinated and BNT162b2 boost-vaccinated individuals (Fig. 3). The neutralizing titer was defined as the maximum dilution giving a reduction of 90% of the cytopathic effect. The cut-off for positive neutralization was ≥1:10 serum dilution. For sera of the 2× BNT162b2-vaccinated persons, the neutralization titer of Delta was significantly reduced compared to wild type SARS-CoV-2. Even more clearly, no neutralization could be detected at all against Omicron for any serum sample. In contrast, sera of 3× BNT162b2 vaccinees showed no statistically significant difference in neutralization of both wt and Delta SARS-CoV-2 virus, highlighting the effective protection of BNT162b2 against Delta VOC. Despite a remarkable increase, neutralization titers against Omicron were still significantly reduced by 1–2 log fold compared to wild type SARS-CoV-2.

Fig. 3
figure 3

Neutralization of SARS-CoV-2 wild type (D614G), Delta, and Omicron. Neutralization of authentic SARS-CoV-2 wt (including D614G mutation), Delta, and Omicron using sera of 2× BNT162b-vaccinated (A) and BNT162b2 boost-vaccinated (B) individuals. Delta, WT, and Omicron 90% neutralization titers (NT90) and median of values are shown from healthcare workers that underwent two-dose vaccination series (a) and three-dose vaccination series (b). Samples were collected 2 weeks and 3 weeks after the last dose, respectively. Reciprocal titers were log10 converted (1 was added to all titers to allow undetectable neutralization to be plotted). Upper and lower dotted lines represent the upper and lower limit of detection (the equivalent of 1:640 and 1:10 titers, respectively). Gray lines represent matched samples from the same donor. Friedman test with Dunn’s multiple comparison was calculated and P values are shown in asterisks


RBD-ACE2 interaction is a prerequisite for SARS-CoV-2 viral entry [8, 9, 26]. Surprisingly, the binding of the Omicron RBD to the ACE2 receptor appears to be reduced in our settings compared to the currently dominant Delta variant, both in an ELISA assay as well as by affinity measurement using MST. Both techniques led to different absolute values caused by the different technique principles [27] but resulted in the same trend. Still, the affinities measured by MST (40.7 nM for Wuhan RBD) were in the same range as the ACE2 affinities determined previously by surface plasmon resonance (44.2 nM) [28]. Several Omicron RBD mutations are assumed to increase the binding to ACE2: G339D, S477N, T478K, Q493K, and N501Y; others are proposed to be neutral: S371L, S373P, G446S, E484A, Q493R, and Q498R, or are assumed to reduce the binding to ACE2: S375F, K417N, G496S, and Y505H according to yeast display experiments performed by Starr et al. [26]. Hence, some bioinformatic models predicted an increase in the ACE2 binding affinity of Omicron RBD [29] while other models rejected this scenario [30, 31] and stated: “the Q493R/K mutations, in a combination with K417N and T478K, dramatically reduced the S1 RBD binding by over 100 folds” [30]. However, the latter considerations are all based on in silico modeling. Thus, RBD-ACE2 interaction involving a heavily mutated RBD, such as the one of Omicron VOC, may deviate from predictions and requires empirical biochemical testing. To our knowledge, this is the first comprehensive empirical analysis of Omicron RBD binding efficacy to the ACE2 receptor. According to our data, the binding of Omicron RBD to human ACE2 was not increased, but rather decreased, especially when compared to Beta and Delta. Despite the observed reduced ACE2 Omicron RBD interaction, ACE2 remains necessary for cell entry shown by a recent study with Omicron pseudotyped viruses [15]. An increased RBD ACE2 binding is leading to increased cell entry shown for Alpha, Beta, Gamma, and Delta [32]. For Omicron, it was shown that the cell binding is reduced (weaker cell-cell fusion activity) when comparing Omicron to Delta [33]. However, the decrease in RBD binding does not necessarily translate into reduced infectivity, as infectivity and replication are also defined by proteolytic spike processing, fusion efficacy, and RNA replication efficiency, just to name a few mechanisms [34,35,36]. Furthermore, the severity of disease depends on several factors, e.g., Delta and Beta show the same affinity to ACE2, but Delta leads to a more severe disease compared to Beta [37]. Nevertheless, our results argue that increased binding to the ACE2 receptors may be an unlikely cause of rapid Omicron spread. One has also to consider that we utilized in our work the originally available sequence with a Q493K mutation, whereas Q493R sequences have been published since. According to Starr et al. [26], the K mutation has an even higher affinity as the R mutation in in vitro binding studies. The here measured reduced binding of Omicron RBD to ACE2 was later confirmed by other studies [38, 39].

Importantly, RBD mutations may also lead to immune escape [40]. The humoral immune answer is a key factor for the antiviral defense [41] and the RBD is the main target of neutralizing antibodies [10, 11, 42]. RBD binding and neutralization capacity do correlate [43, 44]. The very low RBD binding in the Ad26.COV2.S compared to the COVID-19 patient group or the mRNA-vaccinated groups is in accordance with the former results [45] but impaired definite conclusions on Omicron immune escape upon Ad26.COV2.S vaccination. The reduced binding of sera from COVID-19 patients and mRNA vaccinees to the Omicron RBD was in accordance with our and other recent results [14,15,16, 46, 47] describing a highly reduced neutralization of the Omicron variant by human sera from vaccinated persons. However, a 2.6× reduction was observed in RBD binding while in this study the neutralization was under the detection limit for sera from 2× BNT162b2-vaccinated persons and other Omicron SARS-CoV-2 neutralization studies showing a reduction by a magnitude of 10× and more [14,15,16, 46, 47]. Therefore, the Omicron mutations mainly reduce the SARS-CoV-2 neutralization but not the RBD binding in the same measure: This indicates an immune escape focused on serum neutralization evasion. Besides neutralization escape, the reduced affinity seems to be compensated by increased viral replication shown in ex vivo explant cultures of human bronchus [48]. Sera from boost vaccine recipients showed a significant reduction in serum titers as well as 1–2 log fold reduced neutralization of the Omicron variant, whereas the titers and neutralization of the Delta variant did not significantly differ from the wild type. While we have measured a significant decrease of serum binding to Omicron RBD, the boost recipients still had a higher anti-Omicron RBD titer as well as at least a remaining neutralization activity compared to 2× vaccinated individuals. The efficacy of boost immunization in neutralization assays was also observed in other studies [14,15,16]. The timepoint of sampling (duration from vaccination, respectively infection, to sampling) can influence the antibody response. In this study, we focused on a timepoint after vaccination/infection where high antibody titers are expected. Prospective studies with boosted individuals will be pursued in the near future when the availability of subjects with longer time spans after the third dose will be available.

The results of this Omicron RBD study are a snapshot of the current situation. According to the sequencing data deposited as GISAID ( and the analysis on [49], the frequency of the 15 aa mutations in the RBD is very dynamic, e.g., K417N, described for the initial Omicron variant to occur in ~35% (status 2021-12-14, 2146 sequences) of all sequenced Omicron isolates, is now retrieved in above 55% of sequenced viruses (status 2022-02-07, 873.492 sequences). S477N, T478K, and E484A were initially at ~47% (status 2021-12-14, 2146 sequences), now instead above 88%, as N501Y (status 2022-02-07, 873.492 sequences). The K417N mutation is a key mutation also in the Beta variant, the T478K mutation instead in the Delta variant, and N501Y in the Alpha, Beta, and Gamma variants [50]. All of these mutations may contribute to both ACE2 binding efficacy and immune escape. Therefore, Omicron variants with alternative mutations might evolve in the near future and alter the antibody recognition and/or the ACE2 binding efficacy. More comprehensive studies of various subvariants in the Omicron family may shed light on their biochemical and immunological properties and understand the potential for future SARS-CoV-2 evolution.


The Omicron RBD had a lower affinity to ACE2 compared to Beta and Delta, arguing that improved ACE2 binding is not a likely driver of Omicron evolution. Serum antibody titers from COVID-19 patients or mRNA vaccinees were significantly lower against Omicron RBD compared to the original Wuhan strain. Neutralization of Omicron SARS-CoV-2 by the serum of BNT162b2 vaccinees was completely diminished, indicating an immune escape focused on neutralizing antibodies. Nevertheless, a boost vaccination increased the level of anti-RBD antibodies against Omicron, and neutralization of authentic Omicron SARS-CoV-2 was at least partially restored.

Availability of data and materials

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Michael Hust ( This includes antibodies, plasmids, and proteins. All reagents are available on reasonable request after completion of a Material Transfer Agreement.



Human angiotensin-converting enzyme-2


Cytopathic effect


Degree of labeling


Half-maximal effective concentration


Immobilized metal affinity chromatography


Microscale thermophoresis


Receptor binding domain


Size exclusion chromatography


Tissue Culture Infection Dose 50




Variant of concern


  1. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet Lond Engl. 2020;395:565–74.

    Article  CAS  Google Scholar 

  2. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.

    Article  CAS  Google Scholar 

  3. Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern. Accessed 8 Dec 2021.

  4. Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2021;26.

  5. Mwenda M, Saasa N, Sinyange N, Busby G, Chipimo PJ, Hendry J, et al. Detection of B.1.351 SARS-CoV-2 variant strain - Zambia, December 2020. MMWR Morb Mortal Wkly Rep. 2021;70:280–2.

    Article  CAS  Google Scholar 

  6. Muñoz M, Patiño LH, Ballesteros N, Paniz-Mondolfi A, Ramírez JD. Characterizing SARS-CoV-2 genome diversity circulating in South American countries: signatures of potentially emergent lineages? Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;105:329–32.

    Google Scholar 

  7. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet Lond Engl. 2021;397:2331–3.

    Article  CAS  Google Scholar 

  8. Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020.

  9. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh C-L, Abiona O, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–3.

    Article  CAS  Google Scholar 

  10. Bošnjak B, Stein SC, Willenzon S, Cordes AK, Puppe W, Bernhardt G, et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol Immunol. 2021;18:936–44.

    Article  Google Scholar 

  11. Mengist HM, Kombe Kombe AJ, Mekonnen D, Abebaw A, Getachew M, Jin T. Mutations of SARS-CoV-2 spike protein: implications on immune evasion and vaccine-induced immunity. Semin Immunol. 2021;55:101533.

  12. Bertoglio F, Fühner V, Ruschig M, Heine PA, Abassi L, Klünemann T, et al. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep. 2021;36:109433.

  13. Hansen J, Baum A, Pascal KE, Russo V, Giordano S, Wloga E, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020.

  14. Wilhelm A, Widera M, Grikscheit K, Toptan T, Schenk B, Pallas C, et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv. 2021;2021.12.07.21267432. (medRxiv preprint).

  15. Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2021;185(3):447–456.e11.

    Article  Google Scholar 

  16. Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al. Neutralization of SARS-CoV-2 omicron by BNT162b2 mRNA vaccine-elicited human sera. Science. 2022;375(6581):678–80.

    Article  CAS  Google Scholar 

  17. Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-CoV-2: a comparative computational study of spike protein. J Med Virol. 2021.

  18. Bleckmann M, Fritz MH-Y, Bhuju S, Jarek M, Schürig M, Geffers R, et al. Genomic analysis and isolation of RNA polymerase II dependent promoters from Spodoptera frugiperda. PLoS One. 2015;10:e0132898.

    Article  Google Scholar 

  19. Zheng L, Baumann U, Reymond J-L. An efficient one-step site-directed and site-saturation mutagenesis protocol. Nucleic Acids Res. 2004;32:e115.

    Article  Google Scholar 

  20. Korn J, Schäckermann D, Kirmann T, Bertoglio F, Steinke S, Heisig J, et al. Baculovirus-free insect cell expression system for high yield antibody and antigen production. Sci Rep. 2020;10:21393.

    Article  CAS  Google Scholar 

  21. Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12:1577.

    Article  CAS  Google Scholar 

  22. Bertoglio F, Fühner V, Ruschig M, Heine PA, Abassi L, Klünemann T, et al. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Cell Rep. 2021;36:109433.

    Article  CAS  Google Scholar 

  23. Wenzel EV, Bosnak M, Tierney R, Schubert M, Brown J, Dübel S, et al. Human antibodies neutralizing diphtheria toxin in vitro and in vivo. Sci Rep. 2020;10:571.

    Article  CAS  Google Scholar 

  24. Cassaniti I, Bergami F, Percivalle E, Gabanti E, Sammartino JC, Ferrari A, et al. Humoral and cell-mediated response against SARS-CoV-2 variants elicited by mRNA vaccine BNT162b2 in healthcare workers: a longitudinal observational study. Clin Microbiol Infect. 2022;28:301.e1–8.

    Article  Google Scholar 

  25. Percivalle E, Cambiè G, Cassaniti I, Nepita EV, Maserati R, Ferrari A, et al. Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull. 2020;25.

  26. Starr TN, Greaney AJ, Hilton SK, Ellis D, Crawford KHD, Dingens AS, et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell. 2020.

  27. Heinrich L, Tissot N, Hartmann DJ, Cohen R. Comparison of the results obtained by ELISA and surface plasmon resonance for the determination of antibody affinity. J Immunol Methods. 2010;352:13–22.

    Article  CAS  Google Scholar 

  28. Shang J, Ye G, Shi K, Wan Y, Luo C, Aihara H, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–4.

    Article  CAS  Google Scholar 

  29. Shah M, Woo HG. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies; 2021.

    Google Scholar 

  30. Fratev F. The high transmission of SARS-CoV-2 Omicron (B.1.1.529) variant is not only due to its hACE2 binding: a free energy of perturbation study. bioRxiv. 2021;2021.12.04.471246. (bioRxiv preprint).

  31. Glocker MO, Opuni KFM, Thiesen H-J. Compared with SARS-CoV2 wild type’s spike protein, the SARS-CoV2 omicron’s receptor binding motif has adopted a more SARS-CoV1 and/or bat/civet-like structure. bioRxiv. 2021;2021.12.14.472585. (bioRxiv preprint).

  32. Han P, Su C, Zhang Y, Bai C, Zheng A, Qiao C, et al. Molecular insights into receptor binding of recent emerging SARS-CoV-2 variants. Nat Commun. 2021;12:6103.

    Article  CAS  Google Scholar 

  33. Zhao H, Lu L, Peng Z, Chen L-L, Meng X, Zhang C, et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg Microbes Infect. 2022;11:277–83.

    Article  CAS  Google Scholar 

  34. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A. 2009;106:5871–6.

    Article  CAS  Google Scholar 

  35. Pachetti M, Marini B, Benedetti F, Giudici F, Mauro E, Storici P, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020;18:179.

    Article  CAS  Google Scholar 

  36. Hörnich BF, Großkopf AK, Schlagowski S, Tenbusch M, Kleine-Weber H, Neipel F, et al. SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in their requirements for receptor expression and proteolytic activation. J Virol. 2021;95:e00002–21.

    Article  Google Scholar 

  37. Butt AA, Dargham SR, Chemaitelly H, Al Khal A, Tang P, Hasan MR, et al. Severity of illness in persons infected with the SARS-CoV-2 Delta variant vs Beta variant in Qatar. JAMA Intern Med. 2022;182:197–205.

    Article  Google Scholar 

  38. Wu L, Zhou L, Mo M, Liu T, Wu C, Gong C, et al. SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2. Signal Transduct Target Ther. 2022;7:1–3.

    Article  Google Scholar 

  39. Dejnirattisai W, Huo J, Zhou D, Zahradník J, Supasa P, Liu C, et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022;185:467–484.e15.

    Article  CAS  Google Scholar 

  40. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409–24.

    Article  CAS  Google Scholar 

  41. Ng KW, Faulkner N, Wrobel AG, Gamblin SJ, Kassiotis G. Heterologous humoral immunity to human and zoonotic coronaviruses: aiming for the Achilles heel. Semin Immunol. 2021;55:101507.

  42. Zahradník J, Marciano S, Shemesh M, Zoler E, Harari D, Chiaravalli J, et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nat Microbiol. 2021;6:1188–98.

    Article  Google Scholar 

  43. Marcotte H, Piralla A, Zuo F, Du L, Cassaniti I, Wan H, et al. Immunity to SARS-CoV-2 up to 15 months after infection. iScience. 2022;25(2):103743.

  44. Carreño JM, Alshammary H, Tcheou J, Singh G, Raskin A, Kawabata H, et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. 2021.

  45. Dulovic A, Kessel B, Harries M, Becker M, Ortmann J, Griesbaum J, et al. Comparative magnitude and persistence of SARS-CoV-2 vaccination responses on a population level in Germany. medRxiv. 2021;2021.12.01.21266960. (medRxiv preprint).

  46. Cele S, Karim F, Lustig G, James SE, Hermanus T, Wilkinson E, et al. SARS-CoV-2 evolved during advanced HIV disease immunosuppression has Beta-like escape of vaccine and Delta infection elicited immunity. medRxiv. 2021;2021.09.14.21263564. (medRxiv preprint).

  47. Sievers BL, Chakraborty S, Xue Y, Gelbart T, Gonzalez JC, Cassidy AG, et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci Transl Med. 2022:eabn7842. (in press).

  48. Hui KPY, Ho JCW, Cheung Mc, et al. SARS-CoV-2 omicron variant replicationin human bronchus and lung ex vivo. Nature. 2022.

  49. Accessed 8 Dec 2021.

  50. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. 2021;22:757–73.

    Article  CAS  Google Scholar 

Download references


We would like to thank all the blood donors who agreed to this scientific study.


Open Access funding enabled and organized by Projekt DEAL. We kindly acknowledge the financial support of the European Union for the ATAC (“antibody therapy against corona,” Horizon2020 number 101003650), the MWK Niedersachsen (14-76103-184 CORONA-2/20) for the projects “Antibody generation,” “Neutralization experiments” and “Structure-based analysis of antiviral strategies against CoV-2 target proteins and the Deutsche Herzstiftung” (“Menschliche monoklonale Antikörper gegen SARS-CoV2 zur Prophylaxe gegen COVID-19 bei vorerkrankten Risikopatienten – Unterstützung der Entwicklung”) and the Swedish Research Council. SS was supported by DFG FOR3004. LCS was supported by grants from the Helmholtz Association (EU-Partnering PIE-0008 and Helmholtz campaign COVIPA).

Author information

Authors and Affiliations



MS1, FB1, AP, QPH, LCS, and MH conceptualized the study. MS1, FB1, SS, PAH, JCS, IC, FZ, LD, JK, and SP performed experiments. MM, EVW, FK, MPM, IB, AP, FB2, LH, AS, HM2, MS2, QPM, and LCS collected samples and data and analyzed samples. MS1, FB1, SS, PAH, IC, MAYD, HM1, HM2, MS2, AP, QPH, LCS, and MH analyzed data. MS1, FB1, LH, SD, HM2, MS2, AP, QPH, LCS, and MH wrote the manuscript. FB2, LH, SD, HM2, QPH, LCS, and MH conceived the funding. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Michael Hust.

Ethics declarations

Ethics approval and consent to participate

This study was conducted following the Declaration of Helsinki Ethical Principles. Approval was given from the ethical committee of the Technische Universität Braunschweig (Ethik-Kommission der Fakultät 2 der TU Braunschweig, approval number FV-2020-02). The study in Croatia was approved by the Ethics committee of the Rijeka Clinical Hospital Center (2170-29-02/1-20-2). The study in Italy was performed under the approval of the Institutional Review Board of Policlinico San Matteo (protocol number P_20200029440). The study in Sweden was approved by the ethics committee in Stockholm (Dnr 2020-02646). All the participants provided informed consent.

Consent for publication

Not applicable.

Competing interests

MS1, FB1, SS, PAH, SD, and MH are inventors on a patent application on blocking antibodies against SARS-CoV-2. SD and MH are co-founders and shareholders of CORAT Therapeutics GmbH, a company founded for clinical and regulatory development of COR-101, an antibody for the treatment of hospitalized COVID-19 patients. SD and EVW are co-founders and shareholders of Abcalis GmbH, a company producing antibodies for diagnostics of SARS-CoV-2.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Fig. S1.

SDS-PAGE of the RBD25 variants. 2 μg of the indicated purified RBD25 variant in Laemmli buffer containing 5% beta-mercaptoethanol were heated to 95°C for 10 min and run on 15% SDS-PAGE. Fig. S2. MST measurements of the ACE2-hFc RBD interaction. Triplicates were measured and Hill fit was applied. Fig. S3. Human serum from boost vaccinated persons binding to SARS-CoV-2 Wuhan original strain, Beta, Delta and Omicron RBD. ELISA using sera from persons vaccinated first with Ad26.COV2.S and then boostered with BTN162b2 or persons fully vaccinated with a mRNA vaccine and boostered also with a mRNA vaccine. Kruskal-Wallis test with Dunn’s multiple comparisons test was performed. Geometric mean and 95% confidence interval are represented by error bars.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Schubert, M., Bertoglio, F., Steinke, S. et al. Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. BMC Med 20, 102 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • SARS-CoV-2
  • Omicron variant (B.1.1.529)
  • Delta variant (B.1.617.2)
  • Beta variant (B.1.351)
  • Vaccination
  • Antibody titer
  • COVID-19
  • Virus neutralization
  • Human angiotensin-converting enzyme-2 receptor (ACE2)
  • Receptor-binding domain (RBD)